certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-02. Anything still debated is marked as such rather than presented as settled.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
The dressing is applied to a cleaned wound, and usually used to treat uninfected wounds. The dressings may be used, under medical supervision and with an antibiotic to treat the infection, even where aerobic bacterial infection is present. In addition to treating abrasions, minor incisions and lacerations, and superficial puncture wounds, hydrocolloid dressings are used to cover skin-graft donor sites, burns, and cutaneous ulcers (including pressure ulcers or "bed sores", venous ulcers, and diabetic foot ulcers). Small hydrocolloid patches are sometimes also used for acne, to heal the pimples and avoid scars from them. Large dressings with a consistent, adhesive film across the active side (rather than a central pad of hydrocolloid foam) can be cut into smaller strips or other shapes, for use in place of a traditional adhesive bandage of the same size. An indirectly medical use of strips of hydrocolloid dressing is as an alternative to surgical tape, e.g. to secure a nasogastric tube or CPAP mask to a patient's face.
=== Mechanism of action === Posaconazole works by disrupting the functions of certain fungal and protozoal membrane-bound enzyme systems. It does this by blocking the synthesis and turnover of the eukaryotic cell membrane component ergosterol via the inhibition of an enzyme known as CYP51. Posaconazole is significantly more potent at binding to CYP51 than itraconazole.
5 November – Ross McDonnell, 44, director, cinematographer and photographer. 7 November – Dean Byrne, 39, professional boxer. 10 November – Miah Dennehy, 73, footballer (Walsall, Bristol Rovers, national team). 11 November – Louis Belton, 79, politician, TD (1989–1992 and 1997–2002) and Senator (1993–1997). 12 November – Anna Scher, 78, British-Irish drama school founder. 17 November – Seóirse Bodley, 90, composer. 18 November Ben Dunne, 74, businessman. Anthony Farquhar, 83, Roman Catholic prelate, Auxiliary Bishop of Down and Connor (1983–2015). 19 November – Eddie Linden, 88, poet and editor. Born in Scotland. 20 November – Frankie Connolly, 78, footballer (Cork Hibernians, Cork Alberts). 26 November – Tras Honan, 93, politician, Senator (1977–1992) and Cathaoirleach (1982–1983 and 1987–1989). 30 November – Shane MacGowan, 65, singer-songwriter (The Pogues). Born in England.
== Properties == Silica gel's high specific surface area—around 750–800 m2/g (230,000–240,000 sq ft/oz)—allows it to absorb water readily, making it useful as a desiccant (drying agent). Silica gel is often described as "absorbing" moisture, which may be appropriate when the gel's microscopic structure is ignored, as in silica gel packs or other products. However, material silica gel removes moisture by adsorption onto the surface of its numerous pores rather than by absorption into the bulk of the gel. Silica gel is able to absorb up to 37% of its own weight in moisture in high-humidity environments. This moisture can be released upon heating at about 120 °C (248 °F) for 1–2 hours. This makes it reusable multiple times with very little, if any, loss of efficiency.
Sources: en.wikipedia.org
=== Affiliations === Dunkin' has a close relationship with the Boston Red Sox and the New England Patriots, making commercials at the start of each team's season for promotions. Dunkin' also sponsors other professional sports teams, including the Dallas Cowboys, New York Yankees, New York Mets, Philadelphia Eagles, and Tampa Bay Rays. In 2001, Dunkin' Donuts purchased the naming rights for the former Providence Civic Center, and renamed it the Dunkin' Donuts Center. In 2022, the arena was renamed the Amica Mutual Pavilion. The center is the home for the NCAA and Big East Providence Friars men's basketball team from Providence College as well as the home for the AHL Providence Bruins hockey team. In reference to the center's long association with local college basketball, it is often known locally as "The Dunk". In January 2014, English football club Liverpool announced a multimillion-pound global partnership with the company. Dunkin' Donuts signed a sponsorship deal with the National Women's Hockey League in December 2015. As part of the multi-year agreement, Dunkin’ Donuts is the official hot, iced and frozen coffee of the NWHL. In 2016, Dunkin' became the official "coffee, doughnut and breakfast sandwich partner" of the National Hockey League.
Microbial growth and proliferation can be inhibited by a technique called biopreservation. Biopreservation is achieved by adding antimicrobials or by increasing the acidity of the fish muscle. Most bacteria stop multiplying when the pH is less than 4.5. Acidity is increased by fermentation, marination or by directly adding acids (acetic, citric, lactic) to fish products. Lactic acid bacteria produce the antimicrobial nisin which further enhances preservation. Other preservatives include nitrites, sulphites, sorbates, benzoates and essential oils.
=== Cardioprotection against Ischemic injury === JM Downey was the first to introduce the role of PKC in cardioprotection against ischemia-reperfusion injury in 1994,; this seminal idea stimulated a series of studies which examined the different isoforms of PKC. PKCε has been demonstrated to be a central player in preconditioning in multiple independent studies, with its best known actions at cardiac mitochondria. It was first demonstrated by Ping et al. that in five distinct preconditioning regimens in conscious rabbits, the epsilon isoform of PKC specifically translocated from the cytosolic to particulate fraction. This finding was validated by multiple independent studies occurring shortly thereafter, and has since been observed in multiple animal models and human tissue, as well as in studies employing transgenesis and PKCε activators/inhibitors. Mitochondrial targets of PKCε involved in cardioprotection have been actively pursued, since the translocation of PKCε to mitochondria following protective stimuli is one of the most well-accepted cardioprotective paradigms. PKCε has been shown to target and phosphorylate alcohol dehydrogenase 2 (ALDH2) following preconditioning stimuli, which increased the activity of ALDH2 and reduced infarct size. Moreover, PKCε interacts with cytochrome c oxidase subunit IV (COIV), and preconditioning stimuli evoked phosphorylation of COIV and stabilization of COIV protein and activity.
Sources: en.wikipedia.org
The Don Cossacks flag 3:4 was inaugurated during the Don Cossacks assembly in Novocherkassk, Don Republic, on 4 May 1918 under chiefing of Ataman Pyotr Krasnov. The flag has three colours: blue, yellow, and red. The flag is similar to that of the Ukrainian State, also established in 1918, which the Don Republic bordered to its west.
== Honours == Bengt Mannervik (born Eriksson) studied at the prestigious high school Norra Real in Stockholm and was given the prize for the best graduate in 1962. In 1988 he won the competition among 20 applicants for the internationally advertised Karin and Herbert Jacobsson Professorship of Biochemistry at Uppsala University, originally held by Nobel Prize Laureate Arne Tiselius. In 2013 he was awarded the Björkén Prize of Uppsala University. He was elected to the Academia Europaea in 2023. He was elected to the American Association for Cancer Research, and the Royal Society of Sciences at Uppsala. He is an Honorary Member of the American Society of Biochemistry and Molecular Biology. He was nominated Doctor Jubilaris at Stockholm University in 2022.
Pudafensine (INNTooltip International Nonproprietary Name; developmental code name IP2015 among others) is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) which is under development for the treatment of erectile dysfunction, neuropathic pain, trigeminal neuralgia, vulvodynia, female sexual dysfunction, pain, and substance-related disorders. It is taken orally. The drug has been found to induce penile erection in male rodents and to increase genital blood flow and paracopulatory behaviors in female rodents. A close analogue of pudafensine is the earlier SNDRI NS18283. Pudafensine is under development by Initiator Pharma. As of July 2025, it is in phase 2 clinical trials for erectile dysfunction, phase 1 trials for neuropathic pain, trigeminal neuralgia, and vulvodynia, and the preclinical research stage of development for female sexual dysfunction, pain, and substance-related disorders.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.